Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for cognitive symptoms in adults with schizophrenia
IRCT20101130005280N31Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of atomoxetine in schizophrenia (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: cognitive function. Started Nov 2019; status: completed.
02
Drugs
atomoxetine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20101130005280N31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20101130005280N31.